April 1st 2024
Findings from the phase 2 SPEARHEAD-1 trial demonstrate how T-cell receptor therapy may effectively target solid tumors.
February 29th 2024
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
The 14th Asia-Pacific Primary Liver Cancer Expert Meeting
July 18 - 20, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Link Between Agent Orange, Cancer Confirmed
May 1st 1996WASHINGTON--In an update of its 1994 report, the Institute of Medicine (IOM), of the National Academy of Sciences, has confirmed its original findings of an association between herbicides used in the Vietnam War and various health problems, namely, soft tissue sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, and chloracne.
Combination Therapy for Rare Dermal Sarcoma Effective, Avoids Radical Surgery
April 1st 1996Combined treatment involving surgery and radiotherapy is a reasonable alternative to surgery alone in high-risk patients with dermato-fibrosarcoma protruberans (DFSP), Canadian researchers reported at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting.
Isolation of New Transmissible Herpesvirus Suggests Additional Therapeutic Approaches for KS
March 1st 1996A study demonstrating the existence of a new transmissible herpesvirus may lead to additional therapeutic approaches for Kaposi's sarcoma (KS), a cancer that remains one of the major AIDS-associated malignancies. The study findings were reported at The American Society of Hematology's 37th Annual Meeting in Seattle.
Pathogenesis of AIDS-Related Kaposi's Sarcoma
March 1st 1996Emmanoulides, Miles, and Mitsuyasu have written an excellent review summarizing our current understanding of the pathogenesis of AIDS-related Kaposi's sarcoma (AIDS/KS). The authors cover what is currently well established and also provide their viewpoint on future developments in AIDS/KS. My commentary will highlight some of the major questions related to this complex disease.
Pathogenesis of AIDS-Related Kaposi's Sarcoma
March 1st 1996The occurrence of Kaposi's sarcoma (KS) in patients with HIV infection is more than 7,000 times higher than in the non-HIV infected population. The reason for this association is unclear but may involve decreased immune surveillance as a result of the profound cellular immune deficiency caused by HIV, a sexually transmitted KS-inducing virus, whose KS-transforming capabilities may be enhanced by HIV, or a direct or indirect effect of HIV itself in susceptible individuals.
Study Suggests Foscarnet Might Be Useful in Kaposi's Sarcoma
January 1st 1996SEATTLE--DNA from the recently discovered Kaposi's sarcoma-associated herpesvirus (KSHV) has been isolated in KS lesions as well as some AIDS-related lymphomas, and the new research suggests that foscarnet (Foscavir) may effectively inhibit the virus. Enrique. A. Mesri, PhD, of the Department of Medicine, Cornell University Medical College, reported the findings at the American Society of Hematology (ASH) meeting.
FDA Approves New Indication For Roferon-A in CML Patients
December 1st 1995ROCKVILLE, Md--The Food and Drug Administration has approved a new indication for Roche Laboratories' Roferon-A (interferon alfa-2A recombinant). The agent, previously approved for use in treating hairy cell leukemia and AIDS-related Kaposi's sarcoma, is now also indicated for the treatment of chronic phase, Philadelphia chromosome positive chronic myelogenous leukemia (CML).
ODAC Says DaunoXome Should Be Approved for HIV-Associated KS
August 1st 1995ROCKVILLE, Md--The FDA's Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended approval of DaunoXome (liposomal daunorubicin) as first-line therapy for the treatment of advanced HIV-related Kaposi's sarcoma (KS). The usual treatment, a combination of Adriamycin, bleomycin, and vincristine (ABV), is not well tolerated over the long haul, especially when given with antiretroviral agents (ddI, ddC, and AZT).
DaunoXome Is Recommended for Approval for Kaposi's Sarcoma
July 1st 1995BOULDER, Colo--NeXstar Pharmaceuticals, Inc. has announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended approval of DaunoXome, NeXstar's liposomal formulation of daunorubicin, as first-line therapy for Kaposi's sarcoma. ODAC made its recommendation upon review of the company's amended NDA, which included data from NeXstar's phase III study of 227 HIV-positive patients with advanced Kaposi's sarcoma.
FDA Panel Recommends Approval of Roferon-A for Treatment of CML
June 1st 1995WASHINGTON--The FDA's Biological Response Modifiers Advisory Committee unanimously recommended approval of Hoffmann-La Roche Inc.'s Roferon-A (interferon alfa-2a, recombinant) for the treatment of adult patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML). The interferon is currently approved for use in hairy cell leukemia and AIDS related Kaposi's sarcoma.
Antisense Inhibits Ewing's Sarcoma in Mice
May 1st 1995NEW ORLEANS--A novel therapy, based on antisense RNA technology, targets aberrant fusion products produced by chromosomal translocations and may lead to the loss of tumorigenicity in tumor cells of the Ewing's sarcoma family, a study from Thomas Jefferson University has shown.
New VIG Regimen Is Called Highly Active in Sarcoma
May 1st 1995LISBON, Portugal--A new regimen that employs escalating doses of etoposide (VePesid) and ifosfamide (Ifex), together with G-CSF (Neupogen), appears to be among the most active combinations tested to date in adult soft-tissue sarcoma, according to a report from the Scandinavian Sarcoma Group
Probable New Herpesvirus Linked to Kaposi's Sarcoma
April 1st 1995The 20-year search for an infectious agent associated with Kaposi's sarcoma (KS) may be over. Researchers at Columbia-Presbyterian Medical Center in New York have reported significant evidence directly linking a probable new herpesvirus to
ODAC Recommends Accelerated Approval of Liposomal Doxorubicin for Kaposi's Sarcoma
April 1st 1995ROCKVILLE, Md--After hours of heated debate, the FDA's Oncologic Drugs Advisory Committee (ODAC) decided there was sufficient evidence of efficacy to recommend approval of DOX-SL (pegylated liposomal doxorubicin) for the treatment of AIDS-related Kaposi's sarcoma (KS) in patients who have failed first-line treatment or who cannot tolerate other treatment. The potential benefits of the drug generally outweigh the risks, the committee said.
Commentary (Healey): Current Combined Treatment of High-Grade Osteosarcomas
April 1st 1995There are few success stories in solid tumor oncology that match osteogenic sarcoma. Drs. Damron and Pritchard have chronicled this story, and present a multidisciplinary overview of the current management of conventional osteogenic sarcoma.
Commentary (Rosen/Forscher): Current Combined Treatment of High-Grade Osteosarcomas
April 1st 1995In this issue of ONCOLOGY, Damron and Pritchard discuss combined therapy for high-grade osteosarcoma. This is a nice review of the current status of osteogenic sarcoma, certainly from the point of view of modern surgical management, and for
Viral Origin of KS Appears Confirmed
March 1st 1995WASHINGTON--New research presented at the 2nd National Conference on Human Retroviruses and Related Infections appears to confirm last year's report that a virus is the cause of Kaposi's sarcoma (KS). Its discoverers, Drs. Patrick S. Moore and Yuan Chang of Columbia University, are calling the virus Kaposi sarcoma-associated herpesvirus (KSHV).
Liposomal Tretinoin in Phase II/III Trials in Kaposi's Sarcoma Patients
February 1st 1995CAMBRIDGE, Mass--Genzyme Corporation and Argus Pharmaceuticals, Inc. (The Woodlands, Texas) are cosponsoring a phase II/III clinical trial of TretinoinLF in Kaposi's sarcoma patients. TretinoinLF is Argus' intravenous liposomal formulation of all-trans-retinoic acid.